TY - JOUR
T1 - Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults
T2 - evidence suggestive of the linear progression model
AU - Faulkner, S W
AU - Leigh, D A
AU - Oosterhuis, J W
AU - Roelofs, H
AU - Looijenga, L H
AU - Friedlander, M L
N1 - Copyright 2000 Cancer Research Campaign.
PY - 2000/9
Y1 - 2000/9
N2 - Testicular germ cell tumours (TGCTs) may arise through a process of multi-step carcinogenesis, and loss of heterozygosity (LOH) at specific loci is likely to be an important early event, although this has not been studied in detail. In order to explore the pathogenetic relationships among TGCTs, we investigated the genetic changes in testicular tumours that exhibit a disease continuum through the precursor carcinoma in situ (CIS) to either seminoma (SE) and/or non-seminomatous germ cell tumour (NSGCT). Universal amplification has been performed on 87 TGCT specimens and 36 samples of CIS cells microdissected from single paraffin-embedded tumour sections from 40 patients, including multiple specimens of CIS and TGCT cells of varied histology microdissected from 24 individual patients. Seventy-seven microsatellite markers were used to assay these samples for LOH at candidate regions selected from the literature, mapping to 3q, 5q, 9p, 11p, 11q, 12q, 17p and 18q. Construction of deletion maps for each of these regions identified common sites of deletion at 3q27-q28, 5q31, 5q34-q35, 9p22-p21 and 12q22, which correlate with allelic losses we have also observed in the precursor CIS cells. Evidence for allelic loss at 3q27-q28 was observed in all of the embryonal carcinoma samples analysed. We conclude that inactivation of gene(s) within these regions are likely to be early events in the development and progression of TGCTs. These results also provide molecular evidence in support of the hypothesis that SE is an intermediate stage of development within a single neoplastic pathway of progression from CIS precursor cells to NSGCT.
AB - Testicular germ cell tumours (TGCTs) may arise through a process of multi-step carcinogenesis, and loss of heterozygosity (LOH) at specific loci is likely to be an important early event, although this has not been studied in detail. In order to explore the pathogenetic relationships among TGCTs, we investigated the genetic changes in testicular tumours that exhibit a disease continuum through the precursor carcinoma in situ (CIS) to either seminoma (SE) and/or non-seminomatous germ cell tumour (NSGCT). Universal amplification has been performed on 87 TGCT specimens and 36 samples of CIS cells microdissected from single paraffin-embedded tumour sections from 40 patients, including multiple specimens of CIS and TGCT cells of varied histology microdissected from 24 individual patients. Seventy-seven microsatellite markers were used to assay these samples for LOH at candidate regions selected from the literature, mapping to 3q, 5q, 9p, 11p, 11q, 12q, 17p and 18q. Construction of deletion maps for each of these regions identified common sites of deletion at 3q27-q28, 5q31, 5q34-q35, 9p22-p21 and 12q22, which correlate with allelic losses we have also observed in the precursor CIS cells. Evidence for allelic loss at 3q27-q28 was observed in all of the embryonal carcinoma samples analysed. We conclude that inactivation of gene(s) within these regions are likely to be early events in the development and progression of TGCTs. These results also provide molecular evidence in support of the hypothesis that SE is an intermediate stage of development within a single neoplastic pathway of progression from CIS precursor cells to NSGCT.
KW - Adolescent
KW - Adult
KW - Carcinoma in Situ/genetics
KW - Cell Transformation, Neoplastic
KW - Disease Progression
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Loss of Heterozygosity/genetics
KW - Male
KW - Microsatellite Repeats/genetics
KW - Seminoma/genetics
KW - Testicular Neoplasms/genetics
UR - http://www.scopus.com/inward/record.url?scp=0033812198&partnerID=8YFLogxK
U2 - 10.1054/bjoc.2000.1334
DO - 10.1054/bjoc.2000.1334
M3 - Article
C2 - 10952776
SN - 0007-0920
VL - 83
SP - 729
EP - 736
JO - British journal of cancer
JF - British journal of cancer
IS - 6
ER -